Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimisle...

Verlyn Olsen has experienced terrifying moments since being diagnosed with type 1 diabetes in the 80s.

A simple pill to treat or even cure diabetes could be possible, thanks to University of Alberta research — and funding that is laying vital groundwork.

Our Medical Affairs team hosted cell therapy workshops with islet transplant experts to discuss a roadmap for manufactured cell therapies.

On May 5, 2025, Sanofi announced Health Canada approval of Tzield, the first disease-modifying therapy for type 1 diabetes (T1D). This is a huge win for the T1D community in that it is the first medic...

A simple pill to treat or even cure diabetes could be possible, thanks to University of Alberta research — and funding that is laying vital groundwork.

As of October, 2024, the ICD-10 codes include presymptomatic type 1 diabetes, whereas previously these codes only included type 1 diabetes once it was diagnosed. The codes now present the different st...

This updated clinical practice guideline replaces the previous chapter of Glycemic Management in Adults With Type 1 Diabetes (2018, chapter 12) and updates the glycemic management portions of the Mana...

University of Alberta: Careers@UAlberta.ca

We have developed a five-drug class model that uses routine clinical data to identify optimal glucose-lowering therapies for people with type 2 diabetes. Individuals on model-predicted optimal therapy...